Overview
Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class . These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting factor. Interestingly, current research is underway for the potential benefit of bemiparin in the treatment of tumors and diabetic foot ulcers .
Indication
Bemiparin is indicated in the following cases: To prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism; in the prevention of the thromboembolic disease in non-surgical patients; prevention of clotting in the extracorporeal circuit during hemodialysis; to prevent blood clots in the veins after a major orthopedic surgery in patients with high risk of venous thromboembolism; secondary prevention of venous thromboembolism; recurrence in patients with deep vein thrombosis; transient prevention and treatment of deep vein thrombosis (DVT) .
Associated Conditions
- Extracorporeal Clotting During Hemodialysis
- Thromboembolism
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/10/06 | Not Applicable | Recruiting | |||
2020/10/27 | Phase 3 | UNKNOWN | Clinica Universidad de Navarra, Universidad de Navarra | ||
2020/06/09 | Phase 2 | Terminated | Fundación de investigación HM | ||
2018/07/26 | Early Phase 1 | Completed | |||
2016/06/16 | Phase 3 | UNKNOWN | Instituto de Investigación Marqués de Valdecilla | ||
2016/06/09 | Not Applicable | Completed | Mohamed Sayed Mohamed Abbas | ||
2015/11/18 | Phase 4 | Completed | |||
2013/06/18 | Phase 3 | Completed | Berlin-Chemie AG Menarini Group | ||
2012/06/28 | Not Applicable | Completed | |||
2012/04/30 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 2,500 IU ANTI-XA/0.2 ML | SIN16463P | INJECTION, SOLUTION | 2,500 IU Anti-Xa/0.2 ml | 4/1/2022 | |
| HIBOR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES 3,500 IU ANTI-XA/0.2 ML | SIN16462P | INJECTION, SOLUTION | 3,500 IU Anti-Xa/0.2 ml | 4/1/2022 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Bemiparin Sodium Injection | 国药准字HJ20140019 | 化学药品 | 注射剂 | 11/26/2024 | |
| Bemiparin Sodium Injection | 国药准字HJ20140018 | 化学药品 | 注射剂 | 11/26/2024 | |
| Bemiparin Sodium Injection | H20140019 | 化学药品 | 注射剂 | 3/5/2020 | |
| Bemiparin Sodium Injection | H20140018 | 化学药品 | 注射剂 | 3/5/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.